{
  "first_published_at": "2008-07-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON085187", 
  "title": "Etoricoxib: new prescribing guidelines", 
  "tags": "{\"parsed_therapeutic\": [\"pain-management-palliation\", \"rheumatology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Pain management and palliation\", \"Rheumatology\"]}", 
  "_document_number": 286, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/change_icon.png", 
  "therapeutic_area": [
    "pain-management-palliation", 
    "rheumatology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Etoricoxib: new prescribing guidelines</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: July 2008</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--The European Medicines Agency has completed a review of the benefits and risks of 90 mg etoricoxib (Arcoxia&#9660;) in the treatment of rheumatoid arthritis and ankylosing spondylitis. Product information for etoricoxib will be updated as a result of the review.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>The <a href=\"http://www.emea.europa.eu/\" target=\"_blank\">European Medicines Agency</a> has completed a review of the benefits and risks of 90 mg etoricoxib (Arcoxia&#9660;) in the treatment of rheumatoid arthritis and ankylosing spondylitis. The Agency&rsquo;s <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000094.jsp&murl=menus/about_us/about_us.jsp&mid=WC0b01ac0580028c79\" target=\"_blank\">Committee for Medicinal Products for Human Use</a> has concluded that etoricoxib&rsquo;s benefits outweigh the risks in the treatment of rheumatoid arthritis. Furthermore, the Committee recommended extension of the indication to include ankylosing spondylitis at a dose of 90 mg once a day.</p><p>However, the Committee recommended an update to the existing contraindication in patients with inadequately controlled hypertension to state that patients whose blood pressure is persistently above 140/90 mmHg and inadequately controlled must not receive etoricoxib. Furthermore, high blood pressure should be controlled before starting treatment, and should be monitored for 2 weeks after the start of treatment and regularly thereafter.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Prescribe etoricoxib in accordance with the above updated product information</li>\r\n\t\t\t\t<li>Monitor patients closely for any signs and symptoms of cardiovascular side-effects (eg, fluid retention, high blood pressure, shortness of breath, or chest pain)</li>\r\n\t\t\t</ul></div><p>&nbsp;</p><em>Article citation: Drug Safety Use July 2008; Vol 1, Issue 12: 10</em>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>The <a href=\"http://www.emea.europa.eu/\" target=\"_blank\">European Medicines Agency</a> has completed a review of the benefits and risks of 90 mg etoricoxib (Arcoxia&#9660;) in the treatment of rheumatoid arthritis and ankylosing spondylitis. The Agency&#8217;s <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000094.jsp&amp;murl=menus/about_us/about_us.jsp&amp;mid=WC0b01ac0580028c79\" target=\"_blank\">Committee for Medicinal Products for Human Use</a> has concluded that etoricoxib&#8217;s benefits outweigh the risks in the treatment of rheumatoid arthritis. Furthermore, the Committee recommended extension of the indication to include ankylosing spondylitis at a dose of 90 mg once a day.</p><p>However, the Committee recommended an update to the existing contraindication in patients with inadequately controlled hypertension to state that patients whose blood pressure is persistently above 140/90 mmHg and inadequately controlled must not receive etoricoxib. Furthermore, high blood pressure should be controlled before starting treatment, and should be monitored for 2 weeks after the start of treatment and regularly thereafter.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Prescribe etoricoxib in accordance with the above updated product information</li>\r\n\t\t\t\t<li>Monitor patients closely for any signs and symptoms of cardiovascular side-effects (eg, fluid retention, high blood pressure, shortness of breath, or chest pain)</li>\r\n\t\t\t</ul></div><p>&#160;</p><em>Article citation: Drug Safety Use July 2008; Vol 1, Issue 12: 10</em>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2008-07-01", 
  "date_last_modified": "2010-08-31", 
  "_assets": [], 
  "_item_id": 286, 
  "summary": "", 
  "body": "Article date: July 2008\n\nThe [European Medicines Agency](http://www.emea.europa.eu/) has completed a review of the benefits and risks of 90 mg etoricoxib (Arcoxia▼) in the treatment of rheumatoid arthritis and ankylosing spondylitis. The Agency’s [Committee for Medicinal Products for Human Use](http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000094.jsp&murl=menus/about_us/about_us.jsp&mid=WC0b01ac0580028c79) has concluded that etoricoxib’s benefits outweigh the risks in the treatment of rheumatoid arthritis. Furthermore, the Committee recommended extension of the indication to include ankylosing spondylitis at a dose of 90 mg once a day.\n\nHowever, the Committee recommended an update to the existing contraindication in patients with inadequately controlled hypertension to state that patients whose blood pressure is persistently above 140/90 mmHg and inadequately controlled must not receive etoricoxib. Furthermore, high blood pressure should be controlled before starting treatment, and should be monitored for 2 weeks after the start of treatment and regularly thereafter.\n\nAdvice for healthcare professionals:  \n  \n  * Prescribe etoricoxib in accordance with the above updated product information  \n  * Monitor patients closely for any signs and symptoms of cardiovascular side-effects (eg, fluid retention, high blood pressure, shortness of breath, or chest pain)  \n  \n \n\nArticle citation: Drug Safety Use July 2008; Vol 1, Issue 12: 10\n"
}